Cellectar Biosciences

Cellectar reports results of a phase‑1 study of iopofosin I‑131 plus low‑dose dexamethasone in 31 patients with relapsed/refractory multiple myeloma. Of 26 evaluable patients, 84.6% achieved disease stabilization or better; the overall response rate was 15.4% and 30% among patients who received ≥60 mCi. The main events were predominantly hematologic toxicities, which were considered predictable and reversible; no new safety signals were reported. The authors recommend a phase‑2 fractionated regimen of 15 mCi/m² on day 1 and 7 plus weekly low‑dose dexamethasone; the FDA has granted iopofosin special status for several indications. » More on de.investing.com

Cellectar has enrolled the first patient in an open-label phase-1b dose-escalation study of the radioconjugate CLR-125 (iodine‑125) to treat recurrent or refractory triple‑negative breast cancer. Three dose levels are being evaluated (32.75 mCi over 4 cycles, 62.5 mCi over 3 cycles, 95 mCi over 2 cycles) with roughly 15 patients per arm, along with imaging analyses of tumor uptake and biodistribution. Primary endpoints are safety and tolerability; secondary endpoints are tumor response by RECIST and progression-free survival. Additional study sites are expected to be activated in the second quarter, and Cellectar plans to provide 2026 updates on dosimetry, safety, and efficacy. » More on de.investing.com

Cellectar Biosciences will present quarterly results for the period ending 31 Dec. 2025 on March 4, 2026. Two analysts on average expect earnings per share of -1.225 USD (prior year: -0.300 USD). Revenue for the quarter and the fiscal year is still seen by analysts at 0.0 million USD; average annual earnings per share are projected at -9.270 USD (previous fiscal year: -42.000 USD). » More on finanzen.net